Показать сокращенную информацию
dc.contributor.author | Islamov R. | |
dc.contributor.author | Rizvanov A. | |
dc.contributor.author | Mukhamedyarov M. | |
dc.contributor.author | Salafutdinov I. | |
dc.contributor.author | Garanina E. | |
dc.contributor.author | Fedotova V. | |
dc.contributor.author | Solovyeva V. | |
dc.contributor.author | Mukhamedshina Y. | |
dc.contributor.author | Safiullov Z. | |
dc.contributor.author | Izmailov A. | |
dc.contributor.author | Guseva D. | |
dc.contributor.author | Zefirov A. | |
dc.contributor.author | Kiyasov A. | |
dc.contributor.author | Palotás A. | |
dc.date.accessioned | 2018-09-18T20:23:51Z | |
dc.date.available | 2018-09-18T20:23:51Z | |
dc.date.issued | 2015 | |
dc.identifier.issn | 1566-5232 | |
dc.identifier.uri | https://dspace.kpfu.ru/xmlui/handle/net/139454 | |
dc.description.abstract | © 2015 Bentham Science Publishers. Amyotrophic lateral sclerosis (ALS) is an incurable, chronic, fatal neuro-degenerative disease characterized by progressive loss of moto-neurons and paralysis of skeletal muscles. Reactivating dysfunctional areas is under earnest investigation utilizing various approaches. Here we present an innovative gene-cell construct aimed at reviving inert structure and function. Human umbilical cord blood cells (hUCBCs) transduced with adeno-viral vectors encoding human VEGF, GDNF and/or NCAM genes were transplanted into transgenic ALS mice models. Significant improvement in behavioral performance (open-field and grip-strength tests), as well as increased life-span was observed in rodents treated with NCAM-VEGF or NCAM-GDNF co-transfected cells. Active trans-gene expression was found in the spinal cord of ALS mice 10 weeks after delivering genetically modified hUCBCs, and cells were detectable even 5 months following transplantation. Our gene-cell therapy model yielded prominent symptomatic control and prolonged life-time in ALS. Incredible survivability of xeno-transpanted cells was also observed without any immune-suppression. These results suggest that engineered hUCBCs may offer effective gene-cell therapy in ALS. | |
dc.relation.ispartofseries | Current Gene Therapy | |
dc.subject | Adeno-virus | |
dc.subject | Amyotrophic lateral sclerosis (ALS) | |
dc.subject | Gene-cell therapy | |
dc.subject | Glial cell-derived neuro-trophic factor (GDNF) | |
dc.subject | Human umbilical cord blood cell (hUCBC) | |
dc.subject | Human umbilical cord blood mono-nuclear cell (hUCB-MC) | |
dc.subject | Neural cell adhesion molecule (NCAM) | |
dc.subject | Vascular endothelial growth factor (VEGF) | |
dc.subject | Viral vector | |
dc.title | Symptomatic improvement, increased life-span and sustained cell homing in amyotrophic lateral sclerosis after transplantation of human umbilical cord blood cells genetically modified with adeno-viral vectors expressing a neuro-protective factor and a neural cell adhesion molecule | |
dc.type | Article | |
dc.relation.ispartofseries-issue | 2 | |
dc.relation.ispartofseries-volume | 15 | |
dc.collection | Публикации сотрудников КФУ | |
dc.relation.startpage | 266 | |
dc.source.id | SCOPUS15665232-2015-15-2-SID84928944466 |